CD8-Targeted PET Imaging of Tumor-Infiltrating T Cells in Patients with Cancer: A Phase I First-in-Humans Study of ⁸⁹Zr-Df-IAB22M2C, a Radiolabeled Anti-CD8 Minibody.

ABSTRACT: There is a need for in vivo diagnostic imaging probes that can noninvasively measure tumor-infiltrating CD8+ leukocytes. Such imaging probes could be used to predict early response to cancer immunotherapy, help select effective single or combination immunotherapies, and facilitate the development of new immunotherapies or immunotherapy combinations. This study was designed to optimize conditions for performing CD8 PET imaging with ⁸⁹Zr-Df-IAB22M2C and determine whether CD8 PET imaging could provide a safe and effective noninvasive method of visualizing the whole-body biodistribution of CD8+ leukocytes. Methods: We conducted a phase 1 first-in-humans PET imaging study using an anti-CD8 radiolabeled minibody, ⁸⁹Zr-Df-IAB22M2C, to detect whole-body and tumor CD8+

SUBMITTER: Farwell MD 

PROVIDER: S-EPMC9051598 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature